Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H12N4O8S |
| Molecular Weight | 348.289 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]1O)N2C=NC3=C2N=CNC3=O
InChI
InChIKey=IGYLPKLXFDOQGM-KQYNXXCUSA-N
InChI=1S/C10H12N4O8S/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H,18,19,20)/t4-,6-,7-,10-/m1/s1
| Molecular Formula | C10H12N4O8S |
| Molecular Weight | 348.289 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:48:30 GMT 2023
by
admin
on
Sat Dec 16 10:48:30 GMT 2023
|
| Record UNII |
SJ1W653O6G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1091624-25-7
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
70023-32-4
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
PRIMARY | |||
|
SJ1W653O6G
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
PRIMARY | |||
|
DB05973
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
PRIMARY | |||
|
135494187
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The aim of this study was to determine whether a metabolic resistant purine analog, INO-2002, exerts anti-inflammatory effects in an animal model of acute respiratory distress syndrome. Mice challenged with intratracheal LPS (50 microg) were treated with INO-2002 (30 or 100 mg kg(-1), i.p.) in divided doses at either 1 and 12 h or at 5 and 16 h. After 24 h, bronchoalveolar lavage fluid was obtained to measure leukocyte infiltration by myeloperoxidase levels, lung edema by protein levels, and proinflammatory chemokine (macrophage inflammatory protein 1alpha) and cytokine (TNF-alpha, IL-1, and IL-6) levels. INO-2002 (30 and 100 mg kg(-1)) reduced the LPS-mediated infiltration of leukocytes and edema as evidenced by bronchoalveolar lavage fluid reduction in levels of myeloperoxidase and protein.
|
